NeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Leg Syndrome Treatment

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the newly updated treatment guidelines for the treatment of restless leg syndrome.:

Source: Neurology Read More

Previous PostComplement Inhibition of Zilucoplan Unaffected When Used Concomitantly With IVIg, Plasma Exchange
Next PostCipaglucosidase Alfa/Miglustat Therapy Improves Efficacy Outcomes in Enzyme Replacement Therapy-Experienced Patients With Late-Onset Pompe Disease

NeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Leg Syndrome Treatment

Previous PostComplement Inhibition of Zilucoplan Unaffected When Used Concomitantly With IVIg, Plasma Exchange

Next PostCipaglucosidase Alfa/Miglustat Therapy Improves Efficacy Outcomes in Enzyme Replacement Therapy-Experienced Patients With Late-Onset Pompe Disease

Related Posts

<![CDATA[Advancing Multiple Sclerosis Treatment Through Research-Integrated Clinical Care]]>

<![CDATA[Autopsy Study Demonstrates Tofersen Distribution and SOD1 Reduction in SOD1-ALS ]]>

<![CDATA[THC/CBD Combination Cuts Agitation in Hospice-Eligible Dementia: LiBBY Trial]]>

Categories